Table of Contents
- GLP-1 medications, made easier to compare
- A faster way to sort out what fits
- Quick navigation
- Molecule choices
- Dose ranges, from introductory to full maintenance
- Oral versus injectable options
- FDA-approved products versus non-FDA-approved options
- Ways to obtain GLP-1 medications
- Monitoring and follow-up
- Duration of treatment
- Still not sure which path makes sense for you?
- Book with Dr. Benjamin Caplan, MD
- Source note
GLP-1 medications, made easier to compare
This page is built to help patients make sense of the major decision lines: which molecule, which brand, injection versus pill, FDA-approved versus non-approved, introductory dosing versus full maintenance dosing, how closely you want to be followed, and what kind of treatment relationship you actually want.
The goal is clarity, not hype. Some options are FDA-approved branded medications. Others are compounded or non-approved versions that may look similar on the surface but are not regulated the same way. Those are not interchangeable categories.
FDA-approved molecules now available: semaglutide, tirzepatide, liraglutide, and orforglipron.
Main delivery formats: injections and tablets. Oral options now exist for semaglutide and orforglipron.
Very important divide: FDA-approved branded products versus compounded or non-FDA-approved products. These are not the same category.
Ways to access care, from low-touch telehealth prescribing to relationship-based clinical follow-up with active titration.
Molecule choices
Start here. Most people first need to know the molecule name, the company behind it, the brand name, and whether it comes as an injection, a pill, or both.
Dose ranges, from introductory to full maintenance
Most GLP-1 treatment begins with a lower introductory dose and builds gradually as tolerated. Some low doses are official FDA-labeled starting doses. Very low custom “microdoses” marketed online are not part of any FDA-approved labeled regimen.
The low starting dose is an official ramp-up step, not a maintenance goal for most patients.
Oral semaglutide for weight management uses a distinct dose ladder and should not be assumed equivalent to injectable dosing.
The 2.5 mg dose is a starting dose, not a chronic maintenance dose for most weight-management use.
Same molecule family as Zepbound, but the brand and FDA indication differ (diabetes vs. weight management).
Semaglutide for diabetes and cardiovascular risk reduction. Not the same labeled indication as Wegovy.
Oral semaglutide for diabetes. Its dosing should not be borrowed for obesity care without regard to indication.
A true oral GLP-1 for weight management. Its own molecule and dose ladder, distinct from semaglutide oral forms.
May be marketed as gentler or cheaper. Not automatically FDA-approved simply because they resemble a known molecule.
Oral versus injectable options
For some people, the biggest decision is not the molecule but the format. Pills may feel easier and more familiar. Injections may offer a different potency pathway or adherence experience.
Weekly or daily injections
Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, and Victoza are injectable products. Weekly injections can feel simpler for adherence, while daily injections allow a different rhythm but can feel more demanding over time.
Tablet pathways now matter much more
Wegovy tablets, Rybelsus, Ozempic tablets, and Foundayo make pill-based treatment a real category rather than a fringe alternative. This matters for people who dislike needles, travel often, or want a simpler daily routine.
Convenience is not the only variable
The right choice also depends on indication, cost, insurance coverage, potency expectations, side-effect tolerance, and whether someone values faster escalation, slower titration, or easier day-to-day use.
FDA-approved products versus non-FDA-approved options
This is one of the most important sections on the page. Some products are FDA-approved branded medications with known labeled doses, established manufacturing oversight, and formal prescribing information. Others are not.
Branded, labeled, regulated
These products have reviewed labeling, approved dose ladders, recognized indications, and standardized manufacturing expectations. That does not make them perfect or risk-free. It does mean the regulatory path is clear.
- Known brand and manufacturer
- Known FDA labeling and dose steps
- Known approved indication
- Pharmacy distribution through standard channels
Often cheaper, often less standardized
Compounded GLP-1 products are not FDA-approved. Some programs also combine the active chemistry with extra ingredients, fillers, vitamins, or alternate forms of the molecule. These may be marketed aggressively, but they are not the same as an FDA-approved product by brand.
- Not reviewed by FDA as approved finished products
- May differ in concentration, excipients, or formulation
- May be presented under a telehealth brand rather than the actual compounder
- May be used for custom microdosing pathways that are not on the FDA label
“Looks similar” is not the same as “is the same”
A website can make a product appear equivalent to a branded GLP-1 even when the product source, approval status, concentration, and oversight are fundamentally different. That distinction matters when the goal is safe, sustainable, and transparent treatment.
Sorting this out on your own is hard. It does not have to be.
A focused visit with Dr. Caplan can clarify which medication is appropriate, what is actually approved, and what a realistic plan looks like for your situation.
Ways to obtain GLP-1 medications
Not all access points are the same. The differences affect medication sourcing, safety, and how much guidance you receive along the way.
Direct manufacturer or pharmacy-based access
Prescriptions filled through standard pharmacies, sometimes with insurance or manufacturer-linked savings programs.
- Medication sourcing: Usually FDA-approved branded medications
- Follow-up: Ranges from minimal to moderate depending on the prescribing provider
- Strength: Clear sourcing and standardized products
- Tradeoff: Cost and coverage can be unpredictable without guidance
Low-touch telehealth platforms
Some platforms offer quick access and lower-friction onboarding, often using standardized protocols and streamlined follow-up.
- Medication sourcing: May be FDA-approved or compounded depending on the program
- Follow-up: Often protocol-driven with variable continuity
- Strength: Convenience and speed
- Tradeoff: Less individualized care and limited relationship depth
Guided, personalized, physician-led
Ongoing care with a physician who helps guide medication selection, dosing, and long-term planning and stays with you through the full course of treatment.
- Medication sourcing: Prescriptions filled through standard pharmacies
- Follow-up: Personalized, adaptive, and higher-touch
- Strength: Nuanced decision-making, continuity, and real clinical relationship
- Tradeoff: Visit costs are higher than low-touch options
Compounding-focused programs
Some programs center on compounded GLP-1 products or customized dosing approaches that differ from standard FDA-approved pathways.
- Medication sourcing: Often compounded and not FDA-approved
- Follow-up: Ranges from minimal to structured
- Strength: Lower upfront cost and flexibility in some cases
- Tradeoff: Less standardization, more variability in sourcing and oversight
Monitoring and follow-up
Some people want a simple prescription. Others want real clinical follow-up, especially through the first few months when nausea, constipation, food aversion, fatigue, reflux, dose tolerance, and adherence questions are most likely to surface.
Minimal follow-up
This may work for experienced, uncomplicated patients, but it can leave significant value on the table, particularly in the early months.
- Little real-time troubleshooting when symptoms arise
- Dose increases may feel automatic rather than thoughtful
- Less support for side effects, nutrition adaptation, or long-term sustainability
Guided early optimization
This is often where better outcomes are shaped, especially early on.
- Closer check-ins during the first months of treatment
- Attention to tolerance, appetite, intake, hydration, bowel habits, and practical daily fit
- Intentional titration rather than reflexive escalation to the next labeled dose
- More help aiming for durable results rather than short bursts of rapid progress
Early phase: first 1 to 3 months
Often benefits from more frequent contact. This is when people are learning how the medication feels, how quickly to escalate, and whether the current formulation is even the right fit.
Middle phase
Once someone is tolerating treatment, the focus often shifts to dose matching, pace of progress, nutrition quality, hydration, and avoiding overly aggressive titration simply because the next dose exists.
Maintenance phase
Later care may be lighter in frequency, but it still matters. Goals may evolve from initial weight loss to durability, comfort, metabolic improvement, or preventing rebound weight gain.
Duration of treatment
There is no one universally correct treatment length. The right time horizon depends on response, goals, tolerability, affordability, comorbidities, and personal preference.
Shorter-term use
Some people use treatment for a defined window of months to create momentum, improve metabolic markers, or bridge toward new habits and a different weight set point.
Longer-term maintenance
Others stay on therapy for years or indefinitely, particularly when the medication is functioning more like chronic disease management than a temporary boost. Most clinical evidence suggests weight returns when the medication is stopped.
Flexible or stop-start approaches
Some people move in and out of treatment depending on cost, side effects, life demands, preferences, or changing goals. That can be done thoughtfully, but it benefits significantly from physician guidance.
Still not sure which path makes sense for you?
That is exactly what a physician-guided visit is for. You bring the questions. Dr. Caplan brings 20+ years of clinical experience and the time to actually work through them.
Book with Dr. Benjamin Caplan, MD
Board-certified family physician. Published in the New England Journal of Medicine. 300,000+ patients. The same physician, every visit.
GLP-1 Starting Visit / Onboarding
Explore whether GLP-1 treatment is right for you. Review your health history, goals, and options and leave with a clear, thoughtful plan.
GLP-1 Early Check-In / Optimization
Review appetite, progress, side effects, comfort, and tolerance. Decide together whether dose, timing, or formulation should change.
GLP-1 Progress + Maintenance
Monitor progress, discuss changing needs or symptoms, and adapt the plan to support safe, durable success over the long term.
Source note
Medication availability, dose ladders, and access models change. This page is designed as a practical comparison tool and should be reviewed periodically. The FDA-approved product details summarized here were aligned to current FDA labeling and official company prescribing information at the time this page was prepared.
- FDA prescribing information and official labeling for Wegovy (injection and tablets), including semaglutide strengths and maintenance dosing.
- FDA prescribing information and official labeling for Zepbound and Mounjaro, including tirzepatide start and maintenance dosing.
- FDA prescribing information and official labeling for Saxenda and Victoza, including liraglutide titration pathways.
- FDA prescribing information and official labeling for Rybelsus, Ozempic injection, Ozempic tablets, and Foundayo oral tablets.
- FDA safety communications on compounded and non-FDA-approved GLP-1 products (2025 and 2026).